China approves 2 experimental vaccines to enter clinical trials
Coronavirus chronicle
14 April, 2020, 11:15 am
Last modified: 14 April, 2020, 12:23 pm
The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech and by the Wuhan Institute of Biological Products
China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus that killed over 100,000 people worldwide, state media Xinhua reported on Tuesday.
The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech , and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.
In March, China have the green-light for another clinical trial for a coronavirus vaccine candidate developed by military-backed China's Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio, shortly after US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.